Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Allkem (AKE.AX)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (A$)	Price Target (A$)	Rating
2020-10-12	2.88	2.50	Neutral
2020-11-26	4.01	4.50	Buy
2020-12-10	3.93	4.90	Buy
2021-01-28	5.75	6.50	Buy
2021-02-26	4.66	6.20	Buy
2021-03-04	4.54	6.70	Buy
2021-03-18	5.21	-	No Rating
2021-12-17	9.04	10.75	Buy
2022-01-20	11.09	11.20	Neutral
2022-03-01	9.70	12.40	Buy
2022-03-25	11.01	13.80	Buy
2022-04-07	12.81	15.10	Buy
2022-04-14	13.52	15.15	Buy
2022-07-06	9.60	15.55	Buy
2022-07-21	10.11	15.20	Buy
2022-08-26	13.91	18.60	Buy
2022-10-04	14.49	18.70	Buy
2022-10-21	14.65	17.80	Buy
2022-12-13	13.03	17.90	Buy
2023-01-19	12.61	17.50	Buy
2023-01-24	13.80	19.10	Buy
2023-02-27	11.16	16.60	Buy
2023-04-18	12.06	16.30	Buy
2023-04-20	11.64	15.20	Buy
2023-05-11	14.94	-	No Rating

Disclosures

Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
UBS AG, Australia Branch or an affiliate expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.